Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q4 FY2023 Earnings Presentation
32 slides from Dr. Lal Pathlabs's earnings presentation, May 11, 2023
Slide 1: Exchange filing cover letter for earnings presentation
May 11, 2023 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Earnings Pre
Slide 2: Q4 & FY23 Results Presentation
Dr Lal PathLabs Limited (DLPL) Q4 & FY23 Results Presentation May 2023
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr Lal PathLabs Limited (the “Company”) for use in presentati
Slide 4: Table of Contents
Table of Contents Dr Lal PathLabs – At a Glance 4 Overview of Dr Lal PathLabs 5 Key Performance Highlights 6 Financials 9 Operating Highlights 11 Management Commentary 13 Corporate Overview 14 Shareholding 29 Contact Us 30 DISCLAIMER: This presentation may contain ‘forward-looking’ statements at pla
Slide 5: Dr Lal PathLabs – At a Glance
Dr Lal PathLabs – At a Glance India’s Leading 70+ years of 15% 13% 120% & Trusted experience in 3 Year Revenue 3-Year Equity Dividend Diagnostics the field of CAGR Normalised for FY 22-23 Company diagnostics EBITDA CAGR Largest* diagnostics chain in the country 24% 277 5102 with PAN India presence a
Slide 6: Overview of Dr Lal PathLabs
Overview of Dr Lal PathLabs Established Established consumer healthcare brand in diagnostic services brand Pan-India 277 clinical labs (including National Reference Lab at Delhi and Well-positioned integrated Regional Reference labs at Kolkata, Bangalore & Mumbai), 5,102 in one of the coverage Patie
Slide 7: FY23 – Key Performance Highlights
FY23 – Key Performance Highlights INR 1954 Cr +16% 70.6 MN +18% 26.6 MN +8% Non-Covid Revenue Non-Covid Samples Non-Covid Patients INR 528 Cr 26% INR 2017 Cr -3% Normalised EBITDA* Margin Total Revenue INR 297 Cr 15% INR 12 per share 120% Normalised PAT** Margin Dividend * Normalised EBITDA excl. RS
Slide 8: Q4 FY23 – Key Performance Highlights
Q4 FY23 – Key Performance Highlights INR 480 Cr +14% Non-Covid Revenue INR 131 Cr 27% INR 491 Cr +1% Normalised EBITDA* Margin Total Revenue INR 76 Cr 15% INR 98 Cr 22% Normalised PAT** Margin Swasthfit Revenue Contr. * Normalised EBITDA excl. RSU, CSR & exceptional expenses **Normalised PAT excl. n
Slide 9: Non-COVID, COVID & Allied Revenue
Non-COVID, COVID & Allied Revenue Rs. Cr. Total 486 503 534 486 491 514 482 478 480 420 49 7 10 12 1 8 10 2 8 3 1 7 2 1 8 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Non COVID COVID* COVID Allied 1** COVID Allied 2*** *COVID includes RTPCR and Antibody tests; **COVID Allied 1 includes IL-6 & D-Dimer; **
Slide 10: Financials
Financials Particulars (Rs. Cr.) Q4 FY23 Q4 FY22 Gr % FY'23 FY'22 Gr % Revenue 491 486 1.1% 2,017 2,087 -3.4% Operating Expenditure 360 355 1,489 1,487 Normalised EBITDA 131 131 - 528 600 -12.1% Normalised Margins 26.6% 26.9% 26.2% 28.8% RSU, CSR, Exceptional expenses 15 10 38 40 EBITDA 116 121 -4.4
Slide 11: Financial Highlights
Financial Highlights All figures in Rs. Crore Revenue Normalised EBITDA* Normalised PBT** Normalised PAT** Non Covid Covid 2087 2017 -84% 63 600 396 369 528 494 400 297 +16% 1691 1954 Margin Margin Margin Margin Margin Margin 29% 26% 24% 20% 18% 15% FY22 FY23 FY22 FY23 FY22 FY23 FY22 FY23 * Normalis
Slide 12: Operating Highlights
Operating Highlights % Revenue break-up between B2B and B2C % Revenue break-up region-wise 72 62 26 28 14 16 32 34 FY22 FY23 FY22 FY23 15 14 74 72 29 30 B2C revenue share remains at more than 70% continuously even Witnessed fastest growth in the Western region led by focused after sharp decline in C
Slide 13: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +61 +2007 +3943 277 277 4,731 5,102 9,247 10,599 10,938 216 231 3,705 3,095 6,995 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 No. of Patients (Mn) No. of Samples (Mn) +39% +52% 27.3 26.9 66.0 72.3 19.4 20.3 47.
Slide 14: Management Commentary
Management Commentary Commenting on the performance, (Hony) Brig. Dr. Commenting on the performance, Dr. Om Manchanda, Commenting on the performance, Mr. Bharath Arvind Lal, Executive Chairman said: Managing Director said: Uppiliappan, Chief Executive Officer said: “Today, Dr Lal PathLabs is in a un
Slide 15: Corporate Overview
WIDENING : HORIZONS Ox Lat Pathlabs ‘ : SERVING Corporate Overview
Slide 16: Vision, Mission & Values
Vision, Mission & Values Be the most trusted Customer First healthcare partner, enabling healthier VISION lives Ethics & Integrity To be an undisputed market Quality leader by providing accessible, VALUES affordable, timely and quality healthcare, diagnostics, applying MISSION Accountability insight
Slide 17: Vibrant Outlook
Vibrant Outlook Evaluate best fit inorganic Strongly develop Rest of India opportunities in South, and leverage geographies, through Regional expertise of recently acquired Reference Labs and cluster city Suburban brand in West approach for attractive markets Target to grow ahead of the industry Dee
Slide 18: DLPL Strategy for future growth
DLPL Strategy for future growth Significantly leverage the Enhance high-end test portfolio of strong digital infrastructure super-specialty & bundled test • Deployed AI, data analytics, machine learning • Created specialty verticals like Genevolve to focus on tools to elevate the patient experience
Slide 19: Leveraging digital infrastructure to make life easier for patient
Leveraging digital infrastructure to make life easier for patient New Website Launch Wallet • New age user intuitive website. • Senior Citizen Wallet: Wallet points on every • Responsive , mobile friendly web designs. booking for Senior Citizen Patients. • SEO friendly for improved customer reach •
Slide 20: Summary highlights – Technical Lab Operations
Summary highlights – Technical Lab Operations LACE and the centre Only lab in India to introduce the First lab to introduce the of excellence in Relaunched the Lipid Donor derived cell free DNA ONCOPRO TSO500 Reproductive panels incorporating the (LIQUID BIOPSY) technique for Comprehensive Genomic m
Slide 21: Key ESG Initiatives
Key ESG Initiatives Use of Solar E-billing and e- Use of Electric Panels for Power; payment receipt bikes for sample addition of 50 KW to reduce paper collection solar plant at NRL usage Data centre Water saving virtualization to through treatment prevent heat and & reuse of CO2 emission wastewater
Slide 22: Cyber Security Capability
Cyber Security Capability Data Loss • State-of-the-art data loss prevention technology to monitor and prevent the disclosure of information Prevention • Data classification platform for information labeling and handling according to severity of data • Rights management system to enable persistent da
Slide 23: Genevolve: Genetic Testing Division
Genevolve: Genetic Testing Division Onco Genomics Successful completion of 3 years of Launch Wide Test offering with 160+ New Tests Neuro Genomics Wellness Genomics & Pharmacogenomics are upcoming segment Direct reach of 3000+ Doctors Reproductive Genomics Dedicated Business Development team for Gen
Slide 24: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry Best in the Industry CAP Proficiency Testing Score at 99.5% for National Reference Lab Consistently high EQAS Performance Testing Score at 98.5% for Satellite Labs CAP accreditation 2 labs, NABL accreditation 36 Labs 100+ Quality Digitally enabled Real time
Slide 25: Quality Control Laboratory excellence
Quality Control Laboratory excellence Capability Test Recommendation engine building NABL 133 implementation D L Shah Gold Award for LPL Project ‘Improving Laboratory Performance by developing an in-house automated process to Risk Based Internal Audits monitor Quality control’ PROJECT NEEV- self lea
Slide 26: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Real time 30 minutes slot visibility & booking D2C- Automated lead management for the patient Digital ID card & ratings of Phlebo Auto Routing engine to dynamically to the patient allocate the booking to nearest available phlebotomist Variable model wh
Slide 27: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Group Chief Financial Officer Shankha Banerjee Munender Soperna Jai Prakash Meena Manoj Garg
Slide 28: Key Awards & Recognition
Key Awards & Recognition Gold Award Diagnostic Chain of the Year – West Business Standard Star Best Brands GAPIO Excellence in QCI – D. L. Shah Quality Awards - Awarded by the prestigious Healthcare 2022 Diagnostics Award 2022 Healthcare Awards, from The SME of the year 2022 2022 Economic Times in 2
Slide 29: Key Awards & Recognition
Key Awards & Recognition Data Quest Technology VC Circle Healthcare Computerworld Dr. Om Manchanda honoured and EY Entrepreneur of The Year Award 2015 – Excellence in Summit 2013 – Best Honors Laureate awarded as ‘Healthcare Personality 2019 – Life Sciences & Implementation of Diagnostic Company Pro
Slide 30: Shareholding as of 31st March, 2023
Shareholding as of 31st March, 2023 25.3% FPIS, FDI & NRIs 55.0% Promoter and Promoter 15.4% Group Others 4.3% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 29 29
Slide 31: Contact Us
Contact Us About Dr Lal PathLabs Limited (DLPL) Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests an
Slide 32: Thank you
WIDENING @ Sy HORIZONS Ox Lat Pathlabs oo, e SERVING Thank you